Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity

被引：1
|
作者：
Le, Xiuning [1 ,2 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 04期
关键词：
CELL LUNG-CANCER; MUTATION; OUTCOMES;
D O I：
10.1016/j.jtho.2023.01.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：390 / 392
页数：3
相关论文
共 50 条
  • [41] Heterogeneity of resistance mechanisms in lung adenocarcinoma patients with acquired resistance to EGFR inhibitors
    Mu, Xinmeng Jasmine
    Van Allen, Eli
    Wagle, Nikhil
    Chong, Curtis
    Butaney, Mohit
    Farlow, Deborah
    Getz, Gad
    Jaenne, Pasi A.
    Garraway, Levi A.
    CANCER RESEARCH, 2014, 74 (19)
  • [42] Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway
    Ma, Pengfei
    Fu, Yujie
    Chen, Minjiang
    Jing, Ying
    Wu, Jie
    Li, Ke
    Shen, Ying
    Gao, Jian-Xin
    Wang, Mengzhao
    Zhao, Xiaojing
    Zhuang, Guanglei
    THERANOSTICS, 2016, 6 (08): : 1232 - 1243
  • [43] Understanding resistance to EGFR inhibitors—impact on future treatment strategies
    Deric L. Wheeler
    Emily F. Dunn
    Paul M. Harari
    Nature Reviews Clinical Oncology, 2010, 7 : 493 - 507
  • [44] Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
    Bianco, R
    Troiani, T
    Tortora, G
    Ciardiello, F
    ENDOCRINE-RELATED CANCER, 2005, 12 : S159 - S171
  • [45] Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
    Ercan, Dalia
    Xu, Chunxiao
    Yanagita, Masahiko
    Monast, Calixte S.
    Pratilas, Christine A.
    Montero, Joan
    Butaney, Mohit
    Shimamura, Takeshi
    Sholl, Lynette
    Ivanova, Elena V.
    Tadi, Madhavi
    Rogers, Andrew
    Repellin, Claire
    Capelletti, Marzia
    Maertens, Ophelia
    Goetz, Eva M.
    Letai, Anthony
    Garraway, Levi A.
    Lazzara, Matthew J.
    Rosen, Neal
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Jaenne, Pasi A.
    CANCER DISCOVERY, 2012, 2 (10) : 934 - 947
  • [46] Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
    Giaccone, Giuseppe
    Wang, Yisong
    CANCER TREATMENT REVIEWS, 2011, 37 (06) : 456 - 464
  • [47] A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
    Shao, Jun
    Gu, Yunru
    Guo, Renhua
    Xu, Jiali
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 2571 - 2591
  • [48] C-Met, a marker of resistance to EGFR inhibitors in NSCLC
    Engelman, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 22 - 22
  • [49] EGFR ACTIVATION CONFERS RESISTANCE TO MAPK PATHWAY INHIBITORS IN GLIOMA
    Zhang, Jie
    Hariono, Sujatmi
    Hashizume, Rintaro
    Fan, Qiwen
    James, C. David
    Weiss, William A.
    Nicolaides, Theodore
    NEURO-ONCOLOGY, 2013, 15 : 31 - 32
  • [50] THE ROLE OF AXL IN ACQUIRED RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS
    Lee, Jae Cheol
    Jang, Se Jin
    Choi, Chang-Min
    Kim, Kyu-Pyo
    Lee, Dae-Ho
    Kim, Sang-We
    Lee, Jung-Shin
    Kim, Woo Sung
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S678 - S678
12345